The correlation between telomerase activity and Bax/Bcl-2 ratio in valproic acid-treated MCF-7 breast cancer cell line.
Open Access
- 1 July 2015
- journal article
- Vol. 18 (7) , 700-4
Abstract
Valproic acid (VPA), a drug used in the treatment of neurological disorders, has been shown to have cytotoxic effects on cancer cells through different mechanisms. Telomerase, a ribonucleoprotein reverse transcriptase, is responsible for elongation of the telomere and is activated in cancers. A relation between telomerase activity and resistance to apoptosis has been established. This study focused on probable effects of VPA on MCF-7 cancer cells. In particular, we investigated VPA effects on viability, apoptosis and telomerase activity. Cytotoxicity effects of VPA on MCF-7 cells were determined by neutral red uptake assay. Cells were treated with different concentrations of VPA (0-32 mM) and telomerase activity and Bax and Bcl-2 protein levels were determined using TRAP assay (PCR-ELISA) method and ELISA method, respectively. The cytotoxic effects of different concentration of VPA on MCF-7 cells were observed as a reduction in cell viability and telomerase activity and altered expression of Bcl-2 family protein levels. The results also showed that there is a significant correlation between reduction of telomerase activity and increase in Bax/Bcl-2 ratio (P=0.001). Our study demonstrated that cell viability of MCF-7 cells was decreased after treatment with VPA, probably through a reduction of telomerase activity and an increase in Bax/bcl-2 ratio. Therefore, it could be concluded that VPA is a potent anti-cancer agent for breast cancer cells through inhibition of telomerase activity and induction of apoptosis.Keywords
This publication has 20 references indexed in Scilit:
- Telomerase downregulation induces proapoptotic genes expression and initializes breast cancer cells apoptosis followed by DNA fragmentation in a cell type dependent mannerMolecular Biology Reports, 2013
- Is telomerase a viable target in cancer?Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2012
- Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor CellsMolecular Cancer Therapeutics, 2010
- Sulforaphane Causes Epigenetic Repression of hTERT Expression in Human Breast Cancer Cell LinesPLOS ONE, 2010
- Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cellsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Bcl-2-regulated apoptosis: mechanism and therapeutic potentialCurrent Opinion in Immunology, 2007
- Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivoCancer Research, 2006
- Telomerase therapeutics for cancer: challenges and new directionsNature Reviews Drug Discovery, 2006
- hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathwayOncogene, 2006
- Specific Association of Human Telomerase Activity with Immortal Cells and CancerScience, 1994